All episodes
Ep. 397 - What the U.S. midterms mean for biopharma
Ep. 396 - China’s first-order innovation
Ep. 395 - ESMO analysis & Auchincloss proposal
Ep. 394 - Security concerns in U.S., China reshaping biotech
EEp. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau
Ep. 392 - Biotech markets: Pause before the storm?
Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways
Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look
Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs
Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton
Ep. 384 - Back to School Special: The global FIH trials race
Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick
Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA
Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs
Ep. 380 - AZ-BMS rumors, Replimune, psychedelics
Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard
Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data
Ep. 377 - Trends in life sciences talent with CBRE's Ian Anderson
Ep. 376 - M&A momentum: 3Q public markets preview
Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech
Ep. 374 - Parkinson's deep dive & FDA trial reforms
Ep. 373 - AbbVie M&A, FDA reversals, a CAR T first
Ep. 372 - Biotech IPOs, Biosecure Act, cachexia pipeline
Ep. 371 - Moving faster at the academia-industry interface
Ep. 370 - Calmer waters for FDA; Servier, Lilly deals
Ep. 369 - ASCO advances, China innovation & U.S. science under threat
Ep. 368 - ASCO Preview, China Policy, ADC Linkers
Ep. 367 - FDA, obesity targets and the rise of DACs
Ep. 366 - Europe's need for speed: Bio€quity takeaways
Ep. 365 - Thin ice for Makary, redosing AAVs
Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
Ep. 362 - AACR: Data and de-risking
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
Ep. 360 - FDA’s FIH plans. Plus: billion-dollar deals, funds
Ep. 359 - 2Q markets preview, tariffs and biotech takeouts
Ep. 358 - Europe's biotech challenge
Ep. 357 - Deal-O-rama, Gilead and Tallon's U.K. vision
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
Ep. 354 - East-West Summit Takeaways
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos
Ep. 346 - 2026 Public Markets Preview
Ep. 345 - TAC to the Future. Plus: GSK Deal, MFN
Ep. 344 - JPM Momentum and Asia’s Hotbeds of Innovation
Ep. 343 - JPM Deals, Policy Outlook, Approval Trends
Ep. 342 - 2026 Biotech Kickoff
Ep. 341 - BioCentury's '25-'26 Picks. Plus: BioMarin & Biotech ICYMI
Ep. 340 - Obesity Data, Kymera & FDA Survey Results
Ep. 339 - Biotech M&A, In Vivo CAR Ts & FDA Tumult
Ep. 338 - Semaglutide’s Alzheimer’s Miss. Plus: Vaccine Policy, Cell, Gene Therapy Funding
Ep. 337 - FDA’s Moving Goalposts & China’s Innovation Arc
Ep. 336 - Cautious Optimism and M&A Momentum
Ep. 335 - Neurology's Coming Inflection Point
Ep. 334 - Pazdur’s New FDA Role, SITC & China RNAi
Ep. 333 - Is This Korea’s Biotech Moment?
Ep. 332 - Obesity in Focus. Plus: What’s Next for FDA
Ep. 331 - Metsera M&A Melee & Tidmarsh Ouster
Ep. 330 - China's Innovation Moment
Ep. 329 - Novartis' $12B Avidity Buy. Plus: Base Editors
Ep. 328 - Brain Shuttles, GSK Q&A and FDA Vouchers
Ep. 327 - Where Gene & Cell Therapy Go Next With Evotec's Bernd Mühlenweg
Ep. 326 - Market Outlook, Biosecure Returns, Biotech M&A
Ep. 325 - Pfizer MFN Deal, New Trial Paradigm & Billion $ Fund
Ep. 324 - Genmab, GSK and Drug Pricing
Ep. 323 - Agentic AI: From New Targets to the Clinic
Ep. 322 - Takeaways from BioCentury Grand Rounds Europe
Ep. 321 - Pfizer’s Obesity Play & U.K. in Focus
Ep. 320 - U.K. Biotech, U.S.-China, Insmed
Ep. 319 - David Baltimore’s Legacy, Atlas Fund, MASH Pipeline and more
Ep. 318 - Newco Takes on CV Risk. Plus: Disrupting Vaccines
Ep. 317 - Biotech IPOs, FDA-Stealth & Patent Threat
Ep. 316 - Trends in Pharma Deals
Ep. 315 - China Speed: Data, Deals, First in Class
Ep. 314 - Prasad, Lilly Obesity, Acadia & Biosecure
Ep. 313 - Lessons from FDA's Prasad. Plus: What's next for Novo, Bayer
Ep. 312 - Biotech Progress Report
Ep. 311 - The Asia Deals Landscape, U.K. Biotech & More
Ep. 310 - Sarepta & What's Next for Gene Therapy. Plus: Leading FDA's CDER
Ep. 309 - 3Q Markets Preview; Quantum Computing; Makary’s First 100 Days
Ep. 308 - Grand Rounds - Europe Preview
Ep. 307 - How Cancer Regulation is — and isn’t — Changing at FDA
Ep. 306 - Treg Inflection Point; Biotech's Next Big Story; Tax Bill Consequences
Ep. 305 - FDA's Future; In Vivo CAR T Plays; Psychedelics; CDK2
Ep. 304 - Syncona Reshapes Fund; Lilly's $1B Verve Bet; FDA's 2-Track Future
Ep. 303 - Gene Therapy Safety, Amylin in Obesity & FDA's Future
Ep. 302 - Takeaways from BioCentury Grand Rounds Chicago
Ep. 301 - ASCO’s First-in-Human Trials, Crossover Investors & FDA's Rare Disease Plans
Ep. 300 - Biotech’s $13B Deal Day, ASCO's Hot Targets, Drug Pricing Threat
Ep. 299 - ASCO, EpCAM, Rocket & HK IPOs
Ep. 298 - Takeaways from the 25th Bio€quity Europe